1
|
McAtee R, Wood MW, Daniels JB, Lashnits E. Treatment of Francisella philomiragia bacteremia in a dog. J Vet Intern Med 2024; 38:2358-2361. [PMID: 38738486 PMCID: PMC11256135 DOI: 10.1111/jvim.17104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 05/01/2024] [Indexed: 05/14/2024] Open
Abstract
To describe the diagnosis and successful treatment of systemic francisellosis in a dog. An 11-year-old female spayed Labrador retriever presented for progressive lethargy, hyporexia, and cough. The dog was febrile with a neutrophilia, nonregenerative anemia, thrombocytopenia, and had increased activity in serum of liver-derived enzymes. Francisella philomiragia was isolated from aerobic blood culture. The dog was treated for 6 weeks with enrofloxacin orally. Repeated aerobic blood cultures after 2 and 6 weeks of antibiotic therapy were negative. The dog was clinically normal 7 months after diagnosis with no evidence of relapse.
Collapse
Affiliation(s)
- Rae McAtee
- Department of Medical SciencesUniversity of Wisconsin‐Madison School of Veterinary MedicineMadisonWisconsinUSA
| | - Michael W. Wood
- Department of Medical SciencesUniversity of Wisconsin‐Madison School of Veterinary MedicineMadisonWisconsinUSA
| | - Joshua B. Daniels
- Department of Microbiology, Immunology and PathologyColorado State UniversityFort CollinsColoradoUSA
| | - Erin Lashnits
- Department of Medical SciencesUniversity of Wisconsin‐Madison School of Veterinary MedicineMadisonWisconsinUSA
| |
Collapse
|
2
|
McClosky M, Cole S, Seidel EJ, Hess RS. Clinical Differences in Dogs with Enterococcal Bacteriuria Compared with Other Bacteriuria: A Retrospective, Case-Control Study. J Am Anim Hosp Assoc 2024; 60:53-59. [PMID: 38394693 DOI: 10.5326/jaaha-ms-7355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/05/2023] [Indexed: 02/25/2024]
Abstract
A retrospective case-control study was performed to determine the clinical differences between dogs with enterococcal bacteriuria (n = 96 cases) and control dogs with any other bacteriuria (n = 288). More dogs with nonenterococcal bacteriuria demonstrated lower urinary tract clinical signs such as hematuria, pollakiuria, and stranguria (40% versus 27%, P = .02). Recessed vulva (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.4-4.2, P < .001), hyperadrenocorticism (OR 0.149, 95% CI 0.004-0.066, P = .03), chronic kidney disease (OR 2.29, 95% CI 1.14-4.51, P = .01), and myelopathy (OR 5.77, 95% CI 3.07-10.82, P < .001) were more common in dogs with enterococcal bacteriuria. Enterococcus spp. cases were more likely to have polymicrobial growth than controls (OR 28.52; 95% CI 12.63-69.62, P ≤ .001). Pugs (OR 7.4, 95% CI 2.6-19.9, P < .001), bearded collies (OR 24.3, 95% CI 2.9-205.5, P = .003), and Saint Bernards (OR 17.3, CI 1.9-154.4, P = .01) had increased odds of enterococcal growth compared with mixed-breed dogs. In the control (but not the case) population, there was an association between resolution of clinical signs and administration of antimicrobials (P = .01). The signalment, clinical signs, comorbidities, and response to therapy in dogs with enterococcal bacteriuria are different from dogs with other bacteriuria.
Collapse
Affiliation(s)
- Megan McClosky
- From the Department of Clinical Sciences and Advanced Medicine (M.M., E.J.S., R.S.H.), School of Veterinary Medicine, University of Pennsylvania Philadelphia, Pennsylvania
| | - Stephen Cole
- Department of Pathobiology (S.C.), School of Veterinary Medicine, University of Pennsylvania Philadelphia, Pennsylvania
| | - Emily J Seidel
- From the Department of Clinical Sciences and Advanced Medicine (M.M., E.J.S., R.S.H.), School of Veterinary Medicine, University of Pennsylvania Philadelphia, Pennsylvania
| | - Rebecka S Hess
- From the Department of Clinical Sciences and Advanced Medicine (M.M., E.J.S., R.S.H.), School of Veterinary Medicine, University of Pennsylvania Philadelphia, Pennsylvania
| |
Collapse
|
3
|
Pascutti KM, Dolan JK, Porter LT, Gilor S, Harris AN. Case Report: Septic Pericarditis With Achromobacter xyloxidans in an Immunosuppressed Dog. Front Vet Sci 2022; 9:884654. [PMID: 35664856 PMCID: PMC9158496 DOI: 10.3389/fvets.2022.884654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Accepted: 04/29/2022] [Indexed: 11/17/2022] Open
Abstract
A 5-year-old female spayed French Bulldog presented for anorexia and increased respiratory rate. On presentation, she was dyspneic with stridor and increased bronchovesicular sounds. Point-of-care ultrasound identified pericardial effusion. Thoracic radiographs identified pleural effusion, a wide cranial mediastinum, and multifocal unstructured interstitial pulmonary opacities. Bloodwork revealed a moderate leukocytosis characterized by a mature neutrophilia with a left shift, hypoalbuminemia, mildly increased alkaline phosphatase activity, and moderate hypokalemia. Thoracic CT findings revealed moderate pericardial and bilateral pleural effusion, mediastinal effusion, and moderate cranial mediastinal lymphadenopathy. Diagnostic thoracocentesis and pericardiocentesis revealed septic exudates with bacilli. Two days later, a median sternotomy and pericardiectomy were performed. Aerobic cultures of the effusions grew Achromobacter xylosoxidans ss deitrificans. The patient was treated with Amoxicillin-clavulanate and enrofloxacin for 12 weeks and clinically fully recovered. Achromobacter xylosoxidans has not been reported as a cause of purulent pericarditis and pyothorax in a dog. Uniquely, this patient is suspected of developing this infection secondary to immunosuppression.
Collapse
Affiliation(s)
- Kristina M. Pascutti
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, FL, United States
| | - Jacqueline K. Dolan
- Department of Comparative, Diagnostics and Population Medicine, Gainesville, FL, United States
| | - Lauren T. Porter
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, FL, United States
| | - Shir Gilor
- Department of Comparative, Diagnostics and Population Medicine, Gainesville, FL, United States
| | - Autumn N. Harris
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, FL, United States
- Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, College of Medicine, Gainesville, FL, United States
| |
Collapse
|
4
|
Harrer J, Fejös C, Zablotski Y, Hirschberger J, Wolf G, Rieger A, Mayer C, Dorsch R. Bacterial urinary tract infection and subclinical bacteriuria in dogs receiving antineoplastic chemotherapy. J Vet Intern Med 2022; 36:1005-1015. [PMID: 35524488 PMCID: PMC9151473 DOI: 10.1111/jvim.16410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 03/07/2022] [Accepted: 03/08/2022] [Indexed: 11/30/2022] Open
Abstract
Background Immunosuppressive treatment with glucocorticoids and cyclosporine increases the risk for positive urine cultures (PUCs) in dogs. Objective To investigate the prevalence and incidence of PUC in dogs diagnosed with cancer and treated with antineoplastic chemotherapy while distinguishing between subclinical bacteriuria (SB) and urinary tract infection (UTI). Animals Forty‐six client‐owned dogs with nonurogenital cancer treated with antineoplastic chemotherapy. Methods Prospective observational longitudinal clinical study. Dogs in which a urine culture was performed before the start of and at least once during antineoplastic chemotherapy were included. A McNemar's test was used to investigate if the prevalence of PUC increased during antineoplastic chemotherapy. Positive urine cultures were categorized into SB and UTI and multiple PUCs from the same dog and category were grouped together as 1 episode of PUC. Results Urine culture was positive in 21/185 urine samples in 8/46 dogs. Antineoplastic chemotherapy did not influence the prevalence of PUC (P = 1.00), which was 11% (5/46 dogs; 95% confidence interval: 5‐23%) before the start of and 13% (6/46 dogs; 95% confidence interval: 6‐26%) during antineoplastic chemotherapy. Eight dogs had 10 episodes of PUC; 7/10 episodes were classified as SB, and in 3/10 episodes UTI (chronic prostatitis, prostatic abscess, and emphysematous cystitis) was diagnosed. Escherichia coli was the most common pathogen, isolated in 9/10 episodes. Conclusions and Clinical Importance We did not find evidence that antineoplastic chemotherapy is a major predisposing factor for the development of PUC. Most dogs with PUC had SB.
Collapse
Affiliation(s)
- Julia Harrer
- Clinic of Small Animal Internal Medicine, Centre for Clinical Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Csilla Fejös
- Clinic of Small Animal Internal Medicine, Centre for Clinical Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Yury Zablotski
- Clinic of Small Animal Internal Medicine, Centre for Clinical Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Johannes Hirschberger
- Clinic of Small Animal Internal Medicine, Centre for Clinical Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Georg Wolf
- Department of Veterinary Sciences, Institute of Infectious Diseases and Zoonoses, Faculty of Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Alexandra Rieger
- Department of Veterinary Sciences, Institute of Veterinary Pathology, Faculty of Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Christian Mayer
- Department of Veterinary Sciences, Institute of Veterinary Pathology, Faculty of Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| | - Roswitha Dorsch
- Clinic of Small Animal Internal Medicine, Centre for Clinical Veterinary Medicine, Ludwig-Maximilian-University, Munich, Germany
| |
Collapse
|
5
|
Bruet V, Mosca M, Briand A, Bourdeau P, Pin D, Cochet-Faivre N, Cadiergues MC. Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs. Vet Sci 2022; 9:vetsci9040149. [PMID: 35448647 PMCID: PMC9030482 DOI: 10.3390/vetsci9040149] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 03/13/2022] [Accepted: 03/15/2022] [Indexed: 12/10/2022] Open
Abstract
Pruritus is a common clinical sign in many skin disorders and is currently the main complaint in canine dermatology. Pruritic skin diseases can affect the quality of life of dogs and their owners. Several families of antipruritic drugs are available to help control pruritus in dogs. The aim of this review is to help practitioners select the most appropriate symptomatic treatment in the most frequent situations of dermatological pruritus in dogs. The molecules reviewed here are systemic and topical glucocorticoids, antihistamines, ciclosporin, oclacitinib and lokivetmab. A level of evidence (1, 2 or 3) has been established according to a detailed algorithm for each individual study in the literature published between 1990 and March 2021. The guidelines result from evidence grading using the strength of recommendation taxonomy (SoRT) and clinical recommendations using a thorough methodology.
Collapse
Affiliation(s)
- Vincent Bruet
- Veterinary Dermatology Referral Services, 44100 Nantes, France;
| | - Marion Mosca
- Université de Lyon, VetAgro Sup, Interactions Cells Environment, UPSP 2016.A104, 69280 Marcy l’Etoile, France; (M.M.); (D.P.)
| | - Amaury Briand
- Department of Dermatology, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (A.B.); (N.C.-F.)
| | - Patrick Bourdeau
- Department of Clinical Sciences, ENVN (Oniris) Université de Nantes, 44307 Nantes, France;
| | - Didier Pin
- Université de Lyon, VetAgro Sup, Interactions Cells Environment, UPSP 2016.A104, 69280 Marcy l’Etoile, France; (M.M.); (D.P.)
| | - Noëlle Cochet-Faivre
- Department of Dermatology, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (A.B.); (N.C.-F.)
- UMR BIPAR, Laboratoire de Santé Animale, 94700 Maisons-Alfort, France
| | - Marie-Christine Cadiergues
- Department of Clinical Sciences, Université de Toulouse, ENVT, 31076 Toulouse, France
- INFINITy, Université de Toulouse, Inserm, CNRS, UPS, 31059 Toulouse, France
- Correspondence: ; Tel.: +33-561-193268
| |
Collapse
|
6
|
Denti D, Caldin M, Ventura L, De Lucia M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Vet Dermatol 2022; 33:149-e42. [PMID: 35014745 DOI: 10.1111/vde.13053] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 09/15/2021] [Accepted: 11/09/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND Oclacitinib administered at the licensed dose twice daily for two weeks and then once daily as required is recommended for the treatment of atopic dogs. In some cases, the once-daily regimen is insufficient to control the clinical signs. OBJECTIVES To provide preliminary safety and efficacy data on the prolonged twice-daily administration of oclacitinib in atopic dogs. ANIMALS Fifty-three client-owned atopic dogs. METHODS AND MATERIALS The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. Animal details, treatment dose and duration, concurrent diseases, adjunctive medications and possible adverse events were recorded. Treatment efficacy was assessed retrospectively and, when available, the selected blood parameters before and during the treatment were compared. Statistical analyses of the collected data were performed. RESULTS The median treatment duration was 113 days. Excellent-to-good efficacy was observed in 38 dogs (72%), including 24 of 33 dogs that failed to respond to the once-daily regimen. Eight dogs showed a poor response despite the addition of systemic glucocorticoids. Pyoderma, gastrointestinal signs and otitis externa were the most frequent adverse events recorded whilst on treatment. Blood tests performed in 35 dogs showed slightly decreased leucocyte, neutrophil, eosinophil and monocyte counts that remained within the reference ranges in most cases. Three dogs developed hypercholesterolemia. CONCLUSIONS AND CLINICAL RELEVANCE Prolonged twice-daily administration of oclacitinib generally was well-tolerated and was effective in most of the treated dogs. Regular clinical evaluation and blood tests are advisable for this treatment regimen.
Collapse
Affiliation(s)
- Daria Denti
- Dermatology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| | - Marco Caldin
- Pathology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| | - Laura Ventura
- Department of Statistical Sciences, University of Padova, Via Cesare Battisti 241, Padova, 35121, Italy
| | - Michela De Lucia
- Dermatology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| |
Collapse
|
7
|
Teh H. A review of the current concepts in canine urinary tract infections. Aust Vet J 2021; 100:56-62. [PMID: 34775603 DOI: 10.1111/avj.13127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Accepted: 09/27/2021] [Indexed: 12/01/2022]
Abstract
Traditionally, urinary tract infections (UTIs) have been categorised as either uncomplicated or complicated in veterinary medicine, with treatment differing for the two categories. In human medicine, there is an additional category: Asymptomatic bacteriuria, which is the presence of bacteriuria without symptoms of infection. Escherichia coli (E.coli) is the most common bacterial species involved in UTIs in dogs. Clinical signs can be absent in dogs with complicated UTIs, and this has been likened to asymptomatic bacteriuria (ASB) in people and has been termed subclinical bacteriuria (SBU) with the treatment recommendations for SBU in dogs have been adapted from human recommendations. There is a shift in the current treatment of UTIs to help minimise the development of antimicrobial resistance. Routine screening of dogs with conditions that may predispose them to UTIs has been discouraged as has the treatment of SBU. This has been due to the increase in antimicrobial resistance (AMR).
Collapse
Affiliation(s)
- H Teh
- Translational Research and Clinical Trial Study Group, U-Vet Werribee Animal Hospital, Werribee, Victoria, Australia
| |
Collapse
|
8
|
Harrer J, Dorsch R. [Bacterial urinary tract infection and subclinical bacteriuria in the dog: a current review]. TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE 2020; 48:270-284. [PMID: 32823350 DOI: 10.1055/a-1220-1950] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Bacterial urinary tract infection (UTI) is a common clinical presentation in dogs and a frequent reason for the prescription of antimicrobial drugs. UTI refers to adherence, multiplication and persistence of an infectious agent within the urogenital system. This causes an associated inflammatory response as well as the pertaining clinical signs. Depending on the site of infection, UTI's may be classified as bacterial cystitis, prostatitis or pyelonephritis. In contrast, subclinical bacteriuria (SB) is defined as the presence of a significant number of bacteria in the urine of an individual not showing clinical signs referrable to UTI. UTI's typically occur as a consequence of ascending pathogen migration from the host's own fecal or distal urogenital microbial flora. The most commonly isolated pathogen in cases of UTI and SB is Escherichia coli. The diagnosis is based on clinical signs and the results of urine examination and culture. The recently revised guidelines of the International Society for Companion Animal Infectious Diseases provide detailed recommendations for diagnosis and management of different forms of bacterial UTI's in dogs. Adherence to treatment guidelines will improve treatment success and is imperative in avoiding further deterioration of the antimicrobial resistance situation.
Collapse
Affiliation(s)
- Julia Harrer
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| | - Roswitha Dorsch
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| |
Collapse
|
9
|
|
10
|
Selected cytokine expression in dogs with alergic conjunctivitis: Correlation with disease activity. Res Vet Sci 2020; 130:33-40. [PMID: 32114248 DOI: 10.1016/j.rvsc.2020.02.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 02/18/2020] [Indexed: 11/22/2022]
Abstract
INTRODUCTION Canine allergic conjunctivitis (cAC) is described as the most frequent ocular manifestation associated with canine atopic dermatitis (cAD). OBJECTIVES Clinical and immunological characterization of cAD through IL-6, TNF-α and IL-12 mRNA expression quantification in canine conjunctivae. PROCEDURES Twenty client-owned dogs with both cAC and cAD and twenty-one healthy controls were enrolled and clinician assessed CADESI-04 and grade of ocular signs were calculated. Conjunctival biopsies were performed on all animals and relative quantification of the interleukins mRNA expression performed by qRT-PCR. The correlation between cytokine gene expression and cAC score was evaluated, as well as CADESI-04 values. RESULTS The qRT-PCR showed a significant gene upregulation of respectively 291.48 (p = 1.306e-09) and 4.85 (p = .00033) folds on IL-6 and IL-12 in dogs with allergic conjunctivitis compared to the control group. Regarding the average expression of TNF-α there were no statistical significant differences between both groups (p = .18). Higher cAC scores were associated with enhanced gene expression of TNF-α and IL-12. No correlation was found between the cytokine gene expression levels and the CADESI-04 values. CONCLUSION An increase of IL6 and IL12 in cAC was found in the studied population. These two cytokines may be potential immunotherapy targets cAC classification.
Collapse
|
11
|
Abstract
Canine atopic dermatitis (AD) is one of the most common inflammatory skin diseases in dogs. The pathogenesis is complex and not completely understood. Many therapeutic options are available; however, because of cost, side effects, or a long lag phase, new compounds are constantly produced. This article provides a comprehensive review of the latest compounds for the treatment of canine AD. In addition, a brief review of new studies on conventional medications is provided. For a successful long-term therapeutic approach, it is important to considerate the status of the disease, as well as the patients' and their owners' needs.
Collapse
Affiliation(s)
- Domenico Santoro
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2015 Southwest 16th Avenue, Gainesville, FL 32610, USA.
| |
Collapse
|